CF Research Translation Center and Research Development Program
Seattle Children’s Research Institute
University of Washington
B. Wayne Hughes Building (Building Cure)
1920 Terry Ave
Seattle, WA 98101
Current Pilots
| Funding Source | Principal Investigator Department | Funding Period | Project Title |
|---|---|---|---|
| NIH P30 CFRTC | Sid Venkatesh, PhD ISB and Microbiology | 2025-27 | Microbiome-targeted Diets for Rectifying GI Dysfunction in People with Cystic Fibrosis |
| NIH P30 CFRTC | Anne Manicone, MD Medicine, Pulmonary | 2024-26 | Identifying Novel Compounds to Polarize Macrophages toward Reparative States |
| NIH P30 CFRTC | Vincenzo Cirulli, PhD Medicine, Metabolism | 2024-26 | Derivation of Functional Islet Tissue from CF Patient-derived iPSC |
| CFF RDP | Jim Bruce, PhD Genome Sciences | 2024-26 | Investigation of the diagnostic potential of Pseudomonas aeruginosa protein levels in blood and urine |
| CFF RDP | Dustin Long, MD Medicine, Anesthesiology | 2024-26 | Investigating P. aeruginosa mRNA transcripts as indicators of antibiotic efficacy |
| CFF RDP | Tm Hawn, MD, PhD Medicine, Allergy and Infectious Disease | 2024-25 | Non-tuberculous Mycobacteria & Cystic Fibrosis |
| NIH P30 CFRTC | Patrick Mitchell, PhD Microbiology | 2022-25 | CFTR deficiency modulates epithelial inflammasomes |
| NIH P30 CFRTC | Jarrad Scarlett, MD, PhD Pediatrics, Gastroenterology | 2022-25 | Role of dysfunctional gut-brain signaling in the pathogenesis of cystic fibrosis-related diabetes |
| NIH P30 CFRTC | William Grady, MD Neel Dey, MD Medicine, Gastroenterology | 2022-25 | Colonic inflammation and dysbiosis: Factors that induce colorectal cancer (CRC) in cystic fibrosis |
| CFF RDP | Alison Feder, PhD Genome Sciences | 2022-25 | Evolutionary and mutational drivers of Pseudomonas aeruginosa persistence through Trikafta |
| CFF RDP | Waleed Abuzeid, MD Associate Professor, Otolaryngology | 2020-25 | Disruption of Pseudomonas aeruginosa biofilms using a novel nitric oxide-releasing nanoparticle |
| NH P30 CFRTC | Edward Kelly, PhD Associate Professor, Pharmaceutics | 2020-25 | CF kidney phenotype and potential consequences in the era of CFTR correction |